Toxicidad pulmonar en pacientes oncologicos asociado al uso de bleomicina

Abstract:

Worldwide, there will be approximately 19.3 million new cancer cases and almost 10.0 million cancer deaths in 2020. Bleomycin is a polypeptide antibiotic antineoplastic agent, used clinically, alone or in combination with other drugs to treat head and neck cancer, including cancer of the mouth, lips, cheeks, tongue, palate, throat, tonsils, and sinuses, and cancer of the penis, testicles, cervix, and vulva, Hodgkin's lymphoma, and non-Hodgkin's lymphoma. However, the use of this drug has adverse side effects, among which one of the most serious complications, in terms of morbidity and mortality, is pulmonary toxicity associated with the use of bleomycin in cancer patients. The objective of this work is to determine the level of pulmonary toxicity associated with the use of Bleomycin in the treatment of cancer patients. The applied methodology contemplates a retrospective in a sample of clinical histories of patients of the National Cancer Institute of Study (SOLCA). Once the data has been collected, the statistical tests relevant to the study group will be carried out using connection measures, student's t-test, ANOVA and Chi square to measure differences in means and variances as relevant. How it is expected to obtain the characteristics of cancer patients treated with bleomycin and the type of associated cancer, the degree of effectiveness of the use of this drug, its secondary complications and the incidence of pulmonary toxicity and the quality of life of patients

Año de publicación:

2023

Keywords:

• Fibrosis Pulmonar
• Hospital Solca de Guayaquil
• estudio de casos
• ECUADOR
• CANTÓN GUAYAQUIL
• Estudio retrospectivos
• BLEOMICINA

Fuente:

rraae